Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?

Table 2 Completed studies with subcutaneous semaglutide in obesity and their main conclusions

Study	Ref.	Main conclusion
Step 1	Wilding et al[52], 2021	In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight
Step 2	Davies et al[53], 2021	In adults with overweight or obesity, and type 2 diabetes, semaglutide 2.4 mg once a week achieved a superior and clinically meaningful decrease in body weight compared with placebo
Step 3	Wadden et al[54], 2021	Among adults with overweight or obesity, once-weekly subcutaneous semaglutide compared with placebo, used as an adjunct to intensive behavioral therapy and initial low-calorie diet, resulted in significantly greater weight loss during 68 wk
Step 4	Rubino et al[55], 2022	Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss during 68 wk
Step 6	Kadowaki et al[56], 2022	Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2.4 mg once a week had superior and clinically meaningful reductions in body weight, and greater reductions in abdominal visceral fat area compared with placebo

Step 5: Completed, not published.